Tumor lysis syndrome in widely metastatic small-cell lung cancer

1997 ◽  
Vol 2 (4) ◽  
pp. 235-237 ◽  
Author(s):  
Tsukasa Ohnishi ◽  
Kiyoshi Mori ◽  
Sei Ohta ◽  
Kohei Yokoi ◽  
Naoto Miyazawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Lysis Syndrome ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Lysis

Tumor Lysis Syndrome in Small Cell Lung Cancer: A Case Report and Review of the Literature

Onkologie ◽  
2011 ◽  
Vol 34 (3) ◽  
pp. 129-131 ◽  
Author(s):  
Bassel Jallad ◽  
Tamim Hamdi ◽  
Shadi Latta ◽  
Mohamad-Nour Alhosaini ◽  
Fayez Kheir ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Lysis Syndrome ◽  
Small Cell ◽  
Review Of The Literature ◽  
Small Cell Lung ◽  
Tumor Lysis

Fatal Tumor Lysis Syndrome During Radiotherapy for Non–Small-Cell Lung Cancer

2008 ◽  
Vol 26 (36) ◽  
pp. 6005-6006 ◽  
Author(s):  
Geum Youb Noh ◽  
Du Hwan Choe ◽  
Cheol Hyeon Kim ◽  
Jae Cheol Lee
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Lysis Syndrome ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Lysis

scholarly journals Tumor Lysis Syndrome following a Single Dose of Nivolumab for Relapsed Small-Cell Lung Cancer

2021 ◽  
pp. 1652-1659
Author(s):  
Sarah Maryon Hayes ◽  
Christine Wiese ◽  
Robert Schneidewend
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Checkpoint Inhibitor ◽  
Tumor Lysis Syndrome ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Lysis ◽  
Extensive Evaluation ◽  
Platinum Based Chemotherapy

Tumor lysis syndrome (TLS) is an oncologic emergency most frequently associated with initial treatment of hematologic malignancies and high-tumor burden solid tumors such as small-cell lung cancer (SCLC). Most often, TLS is associated with cytotoxic chemotherapy. In the treatment of SCLC, a paradigm shift has taken place in which immunotherapy is often added to chemotherapy for extensive-stage disease in the frontline setting or as monotherapy in the relapsed setting. Nivolumab is a programmed death 1 receptor blocking antibody previously FDA indicated for the treatment of metastatic SCLC with progression after platinum-based chemotherapy and at least one other line of therapy. Nivolumab, like all immune checkpoint inhibitor therapies, is associated with immune-mediated adverse reactions; however, there are few reported cases of nivolumab-induced TLS. We present a case of nivolumab-induced TLS following a single infusion. An 86-year-old female with a history of widely metastatic SCLC with metastasis to the liver, bone, and lymph nodes presented to the hospital following a fall due to weakness, dizziness, slurred speech, nausea, vomiting, and abdominal pain occurring 6 days after receiving her first nivolumab infusion. After extensive evaluation, the patient was diagnosed with TLS with hyperkalemia, acute renal failure, hyperphosphatemia, and hypocalcemia. She was treated aggressively with intravenous fluids, rasburicase, and sodium polystyrene sulfate (Kayexalate<sup>®</sup>), which resulted in rapid improvement of her electrolytes and renal function. However, despite correction of electrolytes and overall symptomatic improvement, over the course of several days, the patient’s condition rapidly deteriorated with increasing dyspnea, lethargy, confusion, and eventually death. TLS following nivolumab is exceedingly rare. This report highlights the potential risk of development of TLS with checkpoint inhibitor therapy.

scholarly journals Spontaneous Tumor Lysis Syndrome in a Patient with Metastatic Small Cell Lung Cancer: A Case Report

2017 ◽  
Vol 10 (1) ◽  
pp. 392-395 ◽  
Author(s):  
Boonphiphop Boonpheng ◽  
Ghulam Murtaza ◽  
David Ginn
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Lysis Syndrome ◽  
Hematologic Malignancies ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Lysis ◽  
Spontaneous Tumor ◽  
Spontaneous Tumor Lysis Syndrome

Tumor lysis syndrome is an oncologic emergency that usually occurs after chemotherapy in patients with hematologic malignancies. Tumor lysis syndrome is rare in cases of solid tumors, especially when it occurs spontaneously. Herein, we present a case of spontaneous tumor lysis syndrome in a 55-year-old woman who presented with dyspnea and was found to have extensive metastatic small cell lung cancer. She developed acute oliguric renal failure and multiple electrolyte abnormalities requiring hemodialysis. The findings of this case suggest that clinicians should maintain a high index of suspicion for patients with malignancies who demonstrate the classic symptom of laboratory abnormalities even in the absence of chemotherapy.

scholarly journals Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

2013 ◽  
Vol 8 (7) ◽  
pp. e61-e62 ◽  
Author(s):  
Sosipatros A. Boikos ◽  
Patrick M. Forde ◽  
Souvik Chatterjee ◽  
Christine L. Hann
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Lysis Syndrome ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Lysis ◽  
Limited Stage

Tumor Lysis Syndrome in Small Cell Lung Cancer

2001 ◽  
Vol 18 (2) ◽  
pp. 149-152 ◽  
Author(s):  
Andre M. Kallab ◽  
Anand P. Jillella
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Lysis Syndrome ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Lysis

Tumor Lysis Syndrome Induced by Radiotherapy in Non-Small Cell Lung Cancer

2010 ◽  
Vol 9 (2) ◽  
pp. 106
Author(s):  
Dong-Hyo Noh ◽  
Ki-Eun Hwang ◽  
Jeong-Hyun Shin ◽  
Dong Kim ◽  
Kyung-Hwa Cho ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Lysis Syndrome ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Lysis
Sign in / Sign up

Export Citation Format

Share Document